137 related articles for article (PubMed ID: 35852888)
1. Medicare Advantage coverage restrictions for the costliest physician-administered drugs.
Anderson KE; Alexander GC; Ma C; Dy SM; Sen AP
Am J Manag Care; 2022 Jul; 28(7):e255-e262. PubMed ID: 35852888
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage.
Gupta R; Fein J; Newhouse JP; Schwartz AL
BMJ; 2024 Mar; 384():e077797. PubMed ID: 38453187
[TBL] [Abstract][Full Text] [Related]
3. Measuring the Scope of Prior Authorization Policies: Applying Private Insurer Rules to Medicare Part B.
Schwartz AL; Brennan TA; Verbrugge DJ; Newhouse JP
JAMA Health Forum; 2021 May; 2(5):e210859. PubMed ID: 35977311
[TBL] [Abstract][Full Text] [Related]
4. Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries.
Rao T; Kiptanui Z; Dowell P; Triebwasser C; Alexander GC; Harris I
JAMA Netw Open; 2020 Mar; 3(3):e200274. PubMed ID: 32119095
[TBL] [Abstract][Full Text] [Related]
5. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
7. Concentration of Physician Services Across Insurers and Effects on Quality: Early Evidence From Medicare Advantage.
Welch WP; Sen AP; Bindman AB
Med Care; 2019 Oct; 57(10):795-800. PubMed ID: 31415344
[TBL] [Abstract][Full Text] [Related]
8. Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20.
Joyce G; Blaylock B; Chen J; Van Nuys K
Health Aff (Millwood); 2024 Mar; 43(3):391-397. PubMed ID: 38437610
[TBL] [Abstract][Full Text] [Related]
9. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
10. Predictors of orphan drug coverage restrictions in Medicare Part D.
Yehia F; Segal JB; Anderson GF
Am J Manag Care; 2020 Sep; 26(9):e289-e294. PubMed ID: 32930558
[TBL] [Abstract][Full Text] [Related]
11. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
12. Prior Authorization for Opioid Use Disorder Versus Pain Medications: Lessons Learned for Parity Enforcement.
Mark TL; Parish WJ; Weber EM; Zarkin GA
J Stud Alcohol Drugs; 2021 Mar; 82(2):214-218. PubMed ID: 33823968
[TBL] [Abstract][Full Text] [Related]
13. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
14. Variability of COPD inhaler coverage in Medicare Part D.
Wormser B; Socal MP; Anderson G
Am J Manag Care; 2021 May; 27(5):187-193. PubMed ID: 34002960
[TBL] [Abstract][Full Text] [Related]
15. Utilization Management in the Medicare Part D Program and Prescription Drug Utilization.
Andersen MS
Forum Health Econ Policy; 2021 Jun; 24(1):1-34. PubMed ID: 36194915
[TBL] [Abstract][Full Text] [Related]
16. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
[TBL] [Abstract][Full Text] [Related]
17. The extent and growth of prior authorization in Medicare Advantage.
Neprash HT; Mulcahy JF; Golberstein E
Am J Manag Care; 2024 Mar; 30(3):e85-e92. PubMed ID: 38457827
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
19. Association between FDA black box warnings and Medicare formulary coverage changes.
Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
